• Jihad Al-Ajlouni, Abdalla Awidi, Osama Samara, Mahasan Al-Najar, Emad Tarwanah, Mohannad Saleh, Mohammad Awidi, Freh Abu Hassan, Mohammad Samih, Abdulbari Bener, and Manar Dweik.
• *Department of Orthopedic Surgery, Jordan University Hospital, University of Jordan, Amman, Jordan; †Department of Medicine, Thrombosis Haemostasis Laboratory, University of Jordan, Amman, Jordan; ‡Faculty of Medicine, Cell Therapy Center, University of Jordan, Amman, Jordan; §Department of Radiology, Jordan University Hospital, University of Jordan, Amman, Jordan; ¶Faculty of Medicine, University of Jordan, Amman, Jordan; ‖Department of Medical Statistics & Epidemiology, Hamad Medical Corporation, Hamad General Hospital, Doha, Qatar; and #Department of Public Health, Weill Cornell Medical College in Qatar, Doha, Qatar.
• Clin J Sport Med. 2015 Nov 1; 25 (6): 524-8.

ObjectiveTo explore the safety and benefit from intra-articular autologous platelet lysate (PL) injection in early and intermediate knee osteoarthritis.DesignOpen-label prospective study.SettingLaboratory.PatientsAdult patients, aged 35 to 70 years, with a history of chronic pain or swelling on one or both knees and imaging findings (radiograph or magnetic resonance imaging) of degenerative changes in the joint of grade I or II on the Kellgren scale were included.InterventionsAutologous PL was given in the knee joint by percutaneous intra-articular route every 3 weeks for a total of 3 injections.Main Outcome MeasuresResponse was evaluated by nonnormalized Knee Osteoarthritis and Disability Outcome Score (KOOS).ResultsThere was a significant improvement in the 5 aspects evaluated at weeks 32 and 52 compared with baseline. Symptoms score significantly improved at weeks 32 and 52 from a mean of 11.1 at baseline to 9.0 (P < 0.0001) and 8.7 (P < 0.0001). Stiffness score significantly improved at weeks 32 and 52 from 2.2 at baseline to 1.7 (P < 0.022) and 1.6 (P < 0.016). Pain score improved at 32 weeks and at 52 weeks from a baseline of 14.2 to 9.8 (P < 0.0001) and 9.2 (P < 0.0001). Daily Living score improved from 25.0 to 18.7 at 32 weeks (P < 0.0001) and to 15.6 at 52 weeks (P < 0.0001). Sport score improved from 10.7 to 8.4 at 32 weeks (P < 0.0001) and to 8.1 at 52 weeks (P < 0.0001).ConclusionsIntra-articular PL significantly improved score of all aspects evaluated by KOOS. Platelet lysate seems to be a safe product.Clinical RelevanceTo the best of our knowledge, this is the first clinical study addressing the use of autologous PL as a treatment measure for knee osteoarthrosis (KOA). There are no studies published regarding the treatment of KOA by intra-articular injections of PL. The previous studies were on the use of platelet-rich plasma (PRP) treatment for KOA. Platelet-rich plasma use has been in place for several years, however, a standardized protocol has not yet been established. Platelet lysate represents a safe, economical, easy to prepare, and easy to apply source of growth factors in the treatment of KOA. A head-to-head study is needed to compare PRP with PL in KOA.

17 keywords...

hide…